PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form.
Company profile
Ticker
PMCB
Exchange
Website
CEO
Kenneth L. Waggoner
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
Former names
EFOODSAFETY COM INC, NUVILEX, INC.
SEC CIK
Corporate docs
Subsidiaries
Bio Blue Bird AG • Viridis Biotech, Inc. • PharmaCyte Biotech Australia • PharmaCyte Biotech Europe Limited ...
IRS number
621772151
PMCB stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
30 Dec 22
10-Q
2022 Q2
Quarterly report
14 Dec 22
DEF 14A
Definitive proxy
25 Nov 22
8-K
Departure of Directors or Certain Officers
18 Nov 22
PRE 14A
Preliminary proxy
15 Nov 22
8-K
Departure of Directors or Certain Officers
7 Nov 22
8-K
Departure of Directors or Certain Officers
14 Oct 22
8-K
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
7 Oct 22
10-Q
2023 Q1
Quarterly report
14 Sep 22
8-K
Company Appoints Five New Independent Directors to Reconstituted Board
15 Aug 22
Latest ownership filings
SC 13G/A
SABBY MANAGEMENT, LLC
10 Jan 23
3
WAYNE REMELL WALKER
30 Dec 22
4
Daniel Stuart Farb
30 Dec 22
4
Daniel Allen
30 Dec 22
3
ROBERT WEINSTEIN
16 Nov 22
SC 13G
Shay Capital LLC
20 Oct 22
3
Daniel Allen
24 Aug 22
3
JONATHAN SCHECHTER
23 Aug 22
3
JACK E STOVER
23 Aug 22
3
Joshua Silverman
23 Aug 22
Financial summary
| Quarter (USD) | Oct 22 | Jul 22 | Apr 22 | Jan 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Apr 22 | Apr 21 | Apr 20 | Apr 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 76.96 mm | 76.96 mm | 76.96 mm | 76.96 mm | 76.96 mm | 76.96 mm |
| Cash burn (monthly) | 1.76 mm | 831.34 k | 772.87 k | 530.25 k | 626.42 k | 371.18 k |
| Cash used (since last report) | 5.03 mm | 2.38 mm | 2.22 mm | 1.52 mm | 1.80 mm | 1.06 mm |
| Cash remaining | 71.93 mm | 74.58 mm | 74.75 mm | 75.44 mm | 75.17 mm | 75.90 mm |
| Runway (months of cash) | 41.0 | 89.7 | 96.7 | 142.3 | 120.0 | 204.5 |
Institutional ownership, Q3 2022
26.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 29 |
| Opened positions | 2 |
| Closed positions | 4 |
| Increased positions | 9 |
| Reduced positions | 9 |
| 13F shares | Current |
|---|---|
| Total value | 11.81 mm |
| Total shares | 4.92 mm |
| Total puts | 600.02 k |
| Total calls | 73.30 k |
| Total put/call ratio | 8.2 |
| Largest owners | Shares | Value |
|---|---|---|
| Ayrton Capital | 1.03 mm | $2.48 mm |
| Shay Capital | 1.02 mm | $2.44 mm |
| Vanguard | 643.17 k | $1.54 mm |
| K2 Principal Fund | 611.16 k | $1.47 mm |
| Sabby Management | 567.60 k | $1.36 mm |
| Equitec Proprietary Markets | 330.69 k | $794.00 k |
| Csenge Advisory | 200.10 k | $480.00 k |
| Geode Capital Management | 175.61 k | $421.00 k |
| Group One Trading | 75.05 k | $180.00 k |
| Simplex Trading | 65.42 k | $157.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Dec 22 | Farb Daniel Stuart | Stock Option Common Stock | Grant | Acquire A | No | No | 2.97 | 125,000 | 371.25 k | 125,000 |
| 28 Dec 22 | Allen Daniel | Stock Option Common Stock | Grant | Acquire A | No | No | 2.97 | 125,000 | 371.25 k | 125,000 |